Medical Oncologist
Invasive lobular carcinoma (ILC) is the second commonest type of invasive breast cancer. Unlike the much more common invasive ductal carcinoma, ILC cells grow in fine single-file lines rather than forming a firm lump — so it can feel like a vague thickening or area of fullness and can hide on a mammogram. That is why a breast MRI is often used to judge its true extent. ILC is usually hormone-receptor-positive, so endocrine therapy is central. At CION, a woman-headed, tumour-board-led team builds an accurate, imaging-guided plan — without rushed decisions or unnecessary tests.
Invasive lobular carcinoma (ILC) is the second commonest type of invasive breast cancer, making up roughly 10–15% of invasive cases. It begins in the lobules — the milk-producing glands of the breast — and then invades the surrounding tissue. The much more common type, invasive ductal carcinoma (IDC), starts in the milk ducts instead. Both are confirmed with a breast biopsy and receptor testing that guide breast cancer treatment.
What makes ILC distinctive is the way it grows. Its cells lose a "glue" protein called E-cadherin, so instead of clumping into a firm ball they spread in fine single-file lines through the breast tissue. As a result, ILC often does not form a clear, distinct lump — it may feel like a vague thickening, fullness, or an area of different texture, which can make it harder to feel on examination and harder to see on a mammogram. ILC is usually hormone-receptor-positive and is more common after menopause.
ILC arises in the milk-producing lobules, while the commoner invasive ductal carcinoma starts in the ducts. The two behave differently enough that the distinction matters.
ILC is the second most frequent invasive breast cancer after ductal carcinoma. It is more common in older, postmenopausal women, though it can occur at any age.
Loss of the E-cadherin protein lets ILC cells grow in thin lines rather than a firm mass — the reason it often causes a vague thickening rather than a clear lump.
Because invasive lobular carcinoma grows in single-file lines rather than a firm mass, mammograms miss a meaningful share of ILCs — studies suggest up to 1 in 5 are not clearly seen. That is why a breast MRI is often added to map the true size of an ILC before surgery, and why any vague but persistent thickening deserves proper evaluation rather than reassurance alone. Source: NCCN Breast Cancer guidance; SEER.
The single biggest thing to understand about ILC is how it differs from invasive ductal carcinoma, which accounts for the great majority of breast cancers. IDC tends to form a firm, distinct lump that is relatively easy to feel and to see on imaging. ILC, by contrast, threads through the breast in single-file lines and frequently does not form a discrete mass at all.
This explains why ILC is often diagnosed at a slightly larger size and why imaging and surgical planning have to be approached with extra care. It does not mean ILC is worse — its outlook is generally good — but it does mean the diagnosis and the plan look different.
ILC begins in the lobules (milk glands); IDC begins in the milk ducts. Both then invade nearby breast tissue, but the starting point shapes how each one grows.
Because ILC cells grow in lines rather than a ball, many women notice a vague thickening, fullness, or area of different texture instead of the classic hard lump people expect.
ILC can blend into normal tissue, so a mammogram may understate or miss it. A breast MRI is often the most reliable way to judge its true extent.
Most ILCs are hormone-receptor-positive and HER2-negative, often lower grade — so endocrine therapy is central rather than chemotherapy for most patients.
Because invasive lobular carcinoma rarely forms a hard, obvious lump, its warning signs are often subtle — which is exactly why they get overlooked. Many women with ILC notice a change in how part of the breast feels rather than a distinct mass. Most breast changes are not cancer, but a change that persists or affects a larger area deserves a proper check rather than reassurance.
Often the first sign of ILC is an area that feels thicker, firmer or fuller than the rest of the breast — without a clearly defined lump. If it does not settle, it should be examined.
An area that simply feels different from the surrounding tissue, or from the same place in the other breast, can be the earliest clue to lobular cancer.
Because ILC can spread through a larger area, one breast may slowly change in size, shape or contour, or feel as if it is being pulled in.
A newly pulled-in (inverted) nipple, or skin that dimples or thickens, can occur with ILC just as with other breast cancers and should always be reviewed.
Diagnosing ILC accurately is genuinely harder than for most breast cancers, and getting it right shapes everything that follows. Because lobular cancer can hide on a mammogram and may understate its true size, the imaging step deserves extra attention. A breast MRI is often the most useful test for showing how far ILC actually extends — which directly affects surgical planning. The full pathway runs from examination and imaging to a core needle biopsy and receptor testing.
A mammogram remains part of the workup, often with ultrasound. They can flag ILC, but may understate its size — so a normal-looking mammogram does not always rule it out.
A breast MRI is especially valuable in ILC because it reveals additional or multifocal areas a mammogram misses — helping the surgeon plan the right operation the first time.
A core needle biopsy takes a small tissue sample so a pathologist can confirm lobular cancer and check its grade. This is the step that turns a suspicion into a diagnosis.
The biopsy report includes ER, PR and HER2 status. Most ILCs are hormone-receptor-positive, which is what makes endocrine therapy the backbone of treatment.
A cancer that hides on a mammogram and spreads in subtle lines is exactly the situation where careful imaging and a team decision matter most. CION is a woman-headed, tumour-board-led organisation built for these decisions — accurate diagnosis, MRI-informed surgical planning, and a treatment plan chosen by a full panel rather than one person.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Woman-led, tumour-board-reviewed, MRI-informed ILC care across 35+ centres in Telangana & AP. Call 1800-202-8726.
Invasive lobular carcinoma is usually lower grade and slower-growing than the average breast cancer, and its outlook is generally good — especially when found early. But it has a few characteristic habits that shape how it is investigated and treated. Compared with invasive ductal carcinoma, ILC is more likely to be multifocal (more than one area in the same breast) and somewhat more likely to occur in both breasts.
This tendency is precisely why imaging and surgical planning need extra care, and why a breast MRI is so often useful. ILC can also, uncommonly, spread to less typical sites such as the abdominal lining, the digestive tract or the ovaries — which is one reason follow-up and any new symptoms are taken seriously, without cause for alarm.
Because most invasive lobular carcinoma is hormone-receptor-positive and lower grade, treatment is built around surgery and a long course of endocrine (hormone) therapy rather than chemotherapy. The first decision — the type and extent of surgery — depends heavily on accurate imaging, which is why a breast MRI often guides whether breast-conserving surgery is feasible or whether a wider operation is wiser.
At CION, this plan is set by the tumour board for your specific situation, drawing on the full picture from diagnosis and staging — so you get the right treatment in the right order, without unnecessary tests or delay.
The outlook for invasive lobular carcinoma is generally good, particularly when it is caught at an early stage. Because most ILC is lower grade and hormone-driven, early-stage disease has high survival rates, comparable to or slightly better than ductal cancer of the same stage in the first years after diagnosis. The most important factors are the stage at diagnosis and whether the cancer has reached the lymph nodes.
ILC does, however, have a tendency to recur later than ductal cancer — sometimes 5, 10 or more years on — which is exactly why staying on endocrine therapy for the full recommended course, and keeping up with follow-up, genuinely matters. These survival figures are population averages; your own outlook depends on your stage and your treatment. At CION, 1-year survival outcomes for breast cancer run meaningfully ahead of the national average.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
No two ILCs are identical, and a good plan is built from several pieces of information rather than a single rule. The pathologist's report from your core needle biopsy, the picture from imaging, and the stage all feed into the tumour board's decisions about surgery, radiation, endocrine therapy and whether chemotherapy adds value.
At CION, these factors are weighed together up front for ILC patients — so the plan reflects your actual cancer, not a generic protocol, and you understand the reasoning behind each step.
An invasive lobular carcinoma diagnosis brings a lot of decisions, and the imaging and surgical choices made early on shape everything that follows. You do not have to navigate them alone. CION offers a clear, woman-led pathway from first consultation to treatment, built around your imaging and your stage — with your first consultation free.
A specialist reviews your biopsy and reports in full, explains what "lobular" means for you, and outlines the likely plan — no rushed decisions, no unnecessary tests.
We confirm receptor status and grade, and use breast MRI where it helps to map true extent — with up to 50% discounts on diagnostics.
3+ oncologists plan your treatment together — typically surgery guided by imaging, radiation where needed, and a long course of endocrine therapy, with chemotherapy only when it adds benefit.
Surgery, radiation, endocrine therapy and chemotherapy as needed — with nutrition, psycho-oncology, long-term follow-up and transparent costs throughout your care.
Hear from patients treated at CION — diagnosis, treatment path, and where they are today.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Invasive lobular carcinoma (ILC) is the second commonest type of invasive breast cancer, making up about 10–15% of cases. It begins in the lobules — the milk-producing glands — and then invades the surrounding breast tissue. What makes it distinctive is that its cells lose a protein called E-cadherin and grow in fine single-file lines rather than a firm clump. As a result, ILC often does not form a clear lump and may feel like a vague thickening. The more common type, invasive ductal carcinoma, starts in the milk ducts and usually forms a more obvious mass.
The biggest difference is the way they grow. Invasive ductal carcinoma usually forms a firm, distinct lump that is relatively easy to feel and to see on imaging. Invasive lobular carcinoma threads through the breast in single-file lines and frequently does not form a discrete mass — so it can feel like a vague thickening and can hide on a mammogram. ILC is also more likely to be multifocal (more than one area) and slightly more likely to occur in both breasts. Most ILC is hormone-receptor-positive and lower grade, so endocrine therapy is central, whereas IDC covers a wider range of subtypes.
Because invasive lobular carcinoma grows in thin lines rather than a solid lump, it can blend into the surrounding normal breast tissue and not stand out clearly on a mammogram. Studies suggest a meaningful share of ILCs — up to about 1 in 5 — are not clearly seen on mammography, and a mammogram may also understate the true size. This is why a breast MRI is often added: it is the most reliable test for showing how far an ILC actually extends, which directly affects surgical planning. A mammogram and ultrasound are still part of the workup, but a normal mammogram does not always rule ILC out.
Often, yes. Because ILC can be more extensive or multifocal than a mammogram suggests, a breast MRI is frequently the most useful test for mapping its true extent before surgery. Knowing exactly how widespread the cancer is helps the surgeon and tumour board decide between breast-conserving surgery and mastectomy, assess the other breast, and reduce the chance of needing a second operation. Not every patient needs an MRI, and the decision is individual — at CION it is made by the tumour board based on your imaging and your situation, so the scan is used where it genuinely changes the plan.
Because most ILC is hormone-receptor-positive and lower grade, treatment is built around surgery and a long course of endocrine (hormone) therapy rather than chemotherapy. Surgery — breast-conserving surgery or mastectomy — is usually the first step, with its extent guided by imaging such as breast MRI. Radiation is generally given after breast-conserving surgery. Endocrine therapy, such as tamoxifen or aromatase inhibitors, is the backbone and is taken for at least 5 years, often longer. Chemotherapy is added only when there are higher-risk features, such as node-positive or higher-grade disease, and gene-expression tests can help decide when it adds benefit.
Early-stage ILC has a generally good outlook, and many early breast cancers are treated with the goal of cure, with a large proportion of women cured. Because most ILC is lower grade and hormone-driven, early disease has high survival rates. The main factors are the stage at diagnosis and whether it has reached the lymph nodes. One important feature is that ILC can recur later than ductal cancer — sometimes many years on — which is why completing the full course of endocrine therapy and keeping up follow-up matters. Advanced disease is generally not curable but is treatable; treatment can control it and extend good-quality life.
Invasive lobular carcinoma has a modestly higher chance of being multifocal (more than one area in the same breast) and of occurring in both breasts compared with ductal cancer. It is not a certainty — most women have cancer in one breast only — but it is the reason the other breast is assessed carefully and why a breast MRI is often valuable at diagnosis. If ILC does spread beyond the breast, it can occasionally reach less typical sites such as the abdominal lining, digestive tract or ovaries; this is uncommon, but it is why any persistent new symptoms during follow-up are checked rather than dismissed.
Yes. CION offers a free first consultation for all cancer patients, including women newly diagnosed with ILC or seeking a second opinion. It is a full 45-minute consultation — a specialist reviews your biopsy and imaging, explains what "lobular" means for your treatment, advises whether a breast MRI would change the surgical plan, and gives you a clear, tumour-board-backed plan. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.